JNJ logo Johnson & Johnson +
Johnson & Johnson
+

Johnson & Johnson (JNJ) Business News

Track Johnson & Johnson in real time with a live news feed covering Johnson & Johnson stock news, official press releases, company announcements, and an archive of historical Johnson & Johnson news. ...more

  • Calendar
    Years
    Get instant access
    Sign up for free
    Get instant access
    Sign up for free
    Month
    Jan
    Feb
    Mar
    Apr
    May
    Jun
    Jul
    Aug
    Sep
    Oct
    Nov
    Dec
    Date
    Su
    Mo
    Tu
    We
    Th
    Fr
    Sa
    Selected Filter
    No selection

How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)

247 Wallst

11:28 AM | Friday | Jun 12, 2026

news photo
Loading...

Twelve thousand dollars a month in dividend income sounds simple enough until you start doing the math. Many investors assume they can reach that number with a seven-figure portfolio and a handful of high-yield stocks. In reality, the capital required ranges from about $1.4 million to more than $4 million, depending on the yield you..
. How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)

Read full article redirect
11:28 AM | Friday | Jun 12, 2026

How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)

247 Wallst

Twelve thousand dollars a month in dividend income sounds simple enough until you start doing the math. Many investors assume they can reach that number with a seven-figure portfolio and a handful of high-yield stocks. In reality, the capital required ranges from about $1.4 million to more than $4 million, depending on the yield you..
. How to Build $12,000 a Month in Dividend Income (And Why Most Investors Underestimate the Cost)

Read full article arrow
News Thumbnail
8:18 AM | Friday | Jun 12, 2026

The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar

247 Wallst

A $50,000 dividend income stream looks unimpressive next to a $100,000 high-yield payout. Twenty years later, the comparison may look very different. That is the entire case for dividend growth investing. The goal is not to maximize income in year one. It is to build an income stream that can keep growing long after a.
.. The Dividend Growth Strategy That Turns $50,000 a Year Into $125,000 Without Investing Another Dollar

Read full article arrow
News Thumbnail
10:46 AM | Thursday | Jun 11, 2026

3 No-Brainer Dividend Growth Stocks to Buy in June

24/7 Wall Street

With the rate environment stabilizing in mid-2026, income investors are circling back to a familiar playbook: own the businesses that have raised payouts through every cycle in living memory.

Read full article arrow
News Thumbnail
10:00 AM | Thursday | Jun 11, 2026

Dividend Safety Check: SNPD and a Portfolio of Dividend Stalwarts

24/7 Wall Street

If you own SNPD (NYSEARCA:SNPD) for the income, the question worth answering is whether the distribution stream is built on companies that can keep paying through a recession or whether it leans on yield-chasing names that crack under pressure.

Read full article arrow
News Thumbnail
9:58 AM | Thursday | Jun 11, 2026

Johnson & Johnson Eyes Rare Disease Expansion

GuruFocus

Johnson and Johnson (JNJ) is making a stronger case for expanding Imaavy into a rare autoimmune blood disorder after posting detailed Phase 2/3 data from its ENER

Read full article arrow
News Thumbnail
8:00 AM | Thursday | Jun 11, 2026

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

GuruFocus

Johnson and Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IO

Read full article arrow
News Thumbnail
7:45 AM | Thursday | Jun 11, 2026

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Business Wire

JACKSONVILLE, Fla.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) is expanding the U.S. roll-out of its latest advancement in presbyopia-correcting intraocular lenses (PC-IOLs). TECNIS PureSee IOL is an extended depth of focus (EDOF) lens designed to support visual clarity and quality for patients undergoing cataract surgery.
3 Benefits of TECNIS PureSee IOL: Range of vision: Excellent distance and intermediate vision with some near vision3* Low level of bothersome visual symptoms: 97% of p.

Read full article arrow
News Thumbnail
7:14 AM | Thursday | Jun 11, 2026

Healthcare ETFs: From Broad Exposure to Big Breakthroughs

ETF Trends

With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.

Read full article arrow
News Thumbnail
5:57 AM | Thursday | Jun 11, 2026

A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell

247 Wallst

A retired couple with a $2 million dividend-focused portfolio yielding roughly 6%, or $120,000 per year, watched their income stream fall by $14,400 during a difficult market period as covered-call funds, mortgage REITs, and business development companies trimmed distributions. Their annual income dropped to $105,600. They did not sell a share. Understanding why they were..
. A $2 Million Dividend Portfolio Cut Its Distribution by $14,400 in One Year and the Holders Did Not Sell

Read full article arrow
News Thumbnail
2:03 AM | Thursday | Jun 11, 2026

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

PRNewsWire

Patients in the IMAAVY 30 mg/kg treatment group a achieved statistically significant durable hemoglobin response b , with mean hemoglobin improvement of at least 1 g/dL as early as Week 1 c   More patients treated with IMAAVY experienced improvement in fatigue d and corticosteroid dose reductions e IMAAVY is designed to target pathogenic immunoglobulin G (IgG) autoantibodies in warm autoimmune hemolytic anemia while preserving immune function Pivotal results will be presented at EHA 2026 STOCKHOLM, June 11, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today is presenting the first comprehensive results from the Phase 2/3 ENERGY study showing that IMAAVY® (nipocalimab-aahu) produced a statistically significant durable hemoglobin (Hgb) responseb with rapid onset of effect in patients with warm autoimmune hemolytic anemia (wAIHA)e in the 30 mg/kg treatment group,a compared with those who received placebo. The randomized, placebo-controlled trial demonstrated approximately three... Read more

Read full article arrow
News Thumbnail